Ireland’s Mr IPO and his plans to make more companies public
Cathal Friel shows no sign of slowing down after a busy week which saw him sell his remaining stake in Hvivo
Open Orphan
Hvivo chairman Cathal Friel sells remaining shares for €7.3m
Businessman oversaw the initial flotation in 2019 of clinical trials group that became Hvivo
Pharmaceutical services company Hvivo sells almost 30m placing shares
New and existing institutional investors indicated demand for shares was in excess of those available
Hvivo signs €7.3m contract to test cold virus treatment
Pharmaceutical services company is testing drug for human rhinovirus in human challenge trial
Poolbeg Pharma uses AI to identify potential drug targets for flu treatment
Biopharmaceutical company hails work with CytoReason as ‘significant breakthrough’
Hvivo inks €5.9m contract with Asia-Pacific biotech to test vaccine
Deal is Dublin-listed pharma company's first in the region in over 10 years
Poolbeg Pharma sees artificial intelligence breakthrough in RSV drug discovery
Company has been working with OneThree Biotech to us artificial intelligence to identify novel drug targets for RSV treatment
Open Orphan appoints Stephen Pinkerton as chief financial officer
Leo Toole has stepped down from the board and CFO role to pursue other interests, company announced on Monday
Open Orphan subsidiary signs deal with global pharma company
Deal will see hVivo manufacture virus for use in human challenge studies
Open Orphan subsidiary signs €6m contract for respiratory study
Company expects revenues from the contract to be recognised across 2022 and 2023
Open Orphan appoints Yamin Khan as new chief executive
Cathal Friel to continue in executive chairman role under new management structure
Potential RSV vaccine achieves regulatory step in US
Bavarian Nordic vaccine candidate used hVivo challenge trial to gather data
Open Orphan subsidiary wins $13.4m contract with US biotech company
Executive chairman Cathal Friel said Hvivo expects to sign a number of similar contracts
Open Orphan subsidiary signs €6.7m contract for flu study
Influenza could be a major global issue due to low immunity caused by reduced infection
Open Orphan wins €9.5m asthma contract with major pharma company
Study is being carried out under asthma human challenge study model
Open Orphan subsidiary develops human study for malaria
Healthy volunteers are administered a pathogenic or virulent strain of virus
Open Orphan pharmaceutical company expands Covid-19 trial
Challenge study is providing valuable insight into biology of the virus, firm says
Open Orphan spin-out Poolbeg Pharma to list on London market
Company will use money from listing to meet costs for flu drug trials, develop assets
Open Orphan gets approval to reduce capital ahead of spin-out
Company says reduction of capital will allow it to return value to its shareholders
Open Orphan subsidiary signs £3m contract for Covid-19 study
hVivo will develop a new SARS-CoV-2 challenge virus based on new emerging variants
Open Orphan plans for possible spin-out of non-core assets
Company says HVO-001 could be included as part of potential demerger
Open Orphan subsidiary wins €7.5m contract to run study
Contract with US biotechnology company concerns a respiratory syncytial virus
Open Orphan gets final go-ahead for Covid-19 human trial
Irish clinical trials group will deliberately infect healthy young volunteers with virus
Open Orphan company successfully completes nasal spray study
Prophylactic spray could be used against Covid-19
Open Orphan renews contract with major pharma company
Dublin-listed pharmaceutical services company says new deal will run for another year
Open Orphan gets green light for Covid-19 nasal vaccine trial
Vaccine could be one of the first to provide long-term immunity from Covid-19
Venn Life Sciences wins another Covid-19 drug study
Open Orphan subsidiary to manage Phase 2 clinical trial for European pharma company
Open Orphan subsidiary takes lead role on guidelines for human challenge agents
Guidelines will cover manufacture of agents for use in controlled infection studies
Coronavirus vaccine: ‘By next summer, Covid will be close to a bad memory’
‘All we have at this point is a very promising press release. But the signs are very promising’
Open Orphan signs two year contract with German pharma company
Contract guarantees annual revenue for Dublin listed company
Open Orphan subsidiary hVivo signs deal for Covid-19 challenge study
Contract with UK government could be worth up to £10m
Open Orphan eyes profitability as it reports £4.1m ebitda loss
Company led by Cathal Friel recorded revenues of £7.1m for its first half
HSE to provide extra 1,500 hospital beds as part of €600m winter plan
Officials warn Covid infections across country ‘a week or two’ behind Dublin
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices